GeNeuro   Report issue

For profit Phase 2
Founded: Geneva Switzerland (2006)

Organization Overview

First Clinical Trial
2011
NCT01699555
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

GeNeuro Australia PTY Ltd | GeNeuro Innovation SAS | GeNeuro SA

Active Ingredients

Drugs in Phase 2 Trials (2)

gnbac1 (7 trials)

tremelimumab (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 2